Savara Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Savara in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Savara stock.
View analyst ratings for Savara or view top-rated stocks.

Wall Street analysts have given Savara a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Savara wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Savara is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Savara.

Savara Inc (NASDAQ:SVRA) released its earnings results on Thursday, May, 13th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by $0.05.
View Savara's earnings history.

Savara's stock was trading at $2.36 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SVRA shares have decreased by 28.0% and is now trading at $1.70.
View which stocks have been most impacted by COVID-19.

4 brokers have issued 1-year price objectives for Savara's shares. Their forecasts range from $3.00 to $7.00. On average, they expect Savara's share price to reach $4.67 in the next twelve months. This suggests a possible upside of 174.5% from the stock's current price.
View analysts' price targets for Savara or view top-rated stocks among Wall Street analysts.

Some companies that are related to Savara include Silence Therapeutics (SLN), Crinetics Pharmaceuticals (CRNX), Praxis Precision Medicines (PRAX), Xenon Pharmaceuticals (XENE), Verastem (VSTM), Evolus (EOLS), Sesen Bio (SESN), Rigel Pharmaceuticals (RIGL), Bicycle Therapeutics (BCYC), IDEAYA Biosciences (IDYA), Calliditas Therapeutics AB (publ) (CALT), Ardelyx (ARDX), Pharming Group (PHAR), Cara Therapeutics (CARA) and Intercept Pharmaceuticals (ICPT).
View all of SVRA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Savara investors own include BioLineRx (BLRX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CEL-SCI (CVM), Geron (GERN), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Verastem (VSTM), Agile Therapeutics (AGRX) and Corbus Pharmaceuticals (CRBP).

Savara trades on the NASDAQ under the ticker symbol "SVRA."

Savara's stock is owned by a number of institutional and retail investors. Top institutional shareholders include NEA Management Company LLC (24.15%), BlackRock Inc. (5.77%), Janus Henderson Group PLC (2.32%), Ikarian Capital LLC (1.72%), Geode Capital Management LLC (0.79%) and Millennium Management LLC (0.44%). Company insiders that own Savara stock include Badrul A Chowdhury, David A Ramsay, David L Lowrance, Joseph S Mccracken and Matthew Pauls.
View institutional ownership trends for Savara.

SVRA stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Brown Advisory Inc., and Northern Trust Corp.
View insider buying and selling activity for Savara or view top insider-selling stocks.

SVRA stock was purchased by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Janus Henderson Group PLC, Ikarian Capital LLC, Millennium Management LLC, Russell Investments Group Ltd., Geode Capital Management LLC, Nuveen Asset Management LLC, and Cubist Systematic Strategies LLC. Company insiders that have bought Savara stock in the last two years include David A Ramsay, David L Lowrance, Joseph S Mccracken, and Matthew Pauls.
View insider buying and selling activity for Savara or or view top insider-buying stocks.

Shares of SVRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SVRA stock can currently be purchased for approximately $1.70.

Savara has a market capitalization of $193.19 million and generates $260,000.00 in revenue each year.

The official website for Savara is www.savarapharma.com.

Savara is headquartered at 6836 Bee Cave Road Building III Suite 200, AUSTIN TX, 78746.

Savara's mailing address is 6836 Bee Cave Road Building III Suite 200, AUSTIN TX, 78746. The company can be reached via phone at 512-614-1848 or via email at [email protected]